Fairfield Financial Advisors’s Roivant Sciences ROIV Stock Holding History

Fairfield Financial Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-500	Closed	-$5.92K	–	161
2024 Q4	$5.92K	Hold	500	–	–	﹤0.01%	219
2024 Q3	$5.77K	Hold	500	–	–	﹤0.01%	245
2024 Q2	$5.29K	Buy	+500	New	+$5.48K	﹤0.01%	240
2023 Q4	$5.62K	Hold	500	–	–	﹤0.01%	264
2023 Q3	$5.84K	Hold	500	–	–	﹤0.01%	252
2023 Q2	$5.04K	Hold	500	–	–	﹤0.01%	272
2023 Q1	$3.65K	Hold	500	–	–	﹤0.01%	281
2022 Q4	$4K	Hold	500	–	–	﹤0.01%	261
2022 Q3	$1.61K	Hold	500	–	–	﹤0.01%	293
2022 Q2	$2.04K	Hold	500	–	–	﹤0.01%	273
2022 Q1	$2.47K	Buy	+500	New	+$3.3K	﹤0.01%	279

Other funds holding ROIV

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Fairfield Financial Advisors's ROIV Position: Q1 2025 in Review

Fairfield Financial Advisors sold out of Roivant Sciences (ROIV) in Q1 2025, closing a stake of 500 shares — an estimated $5.92K sold.

Fairfield Financial Advisors first reported a position in ROIV in Q1 2022 and held it in 11 quarters. The position peaked at $5.92K in Q4 2024. 312 funds tracked by Wall St. Rank hold ROIV as of Q1 2025.

Fairfield Financial Advisors reported no remaining Roivant Sciences position as of Q1 2025 after selling out during the quarter.
Fairfield Financial Advisors sold 500 Roivant Sciences shares in Q1 2025, an estimated $5.92K.
Fairfield Financial Advisors first reported a position in Roivant Sciences in Q1 2022 and held it in 11 quarters.
Fairfield Financial Advisors's Roivant Sciences position peaked at $5.92K in Q4 2024.
312 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2025.

Based on Fairfield Financial Advisors's 13F filing for Q1 2025, filed 9 May 2025.